CA2357986C - Acides nucleiques a extremites bloquees, squelette modifie et stabilite acide et leurs utilisations therapeutiques - Google Patents
Acides nucleiques a extremites bloquees, squelette modifie et stabilite acide et leurs utilisations therapeutiques Download PDFInfo
- Publication number
- CA2357986C CA2357986C CA2357986A CA2357986A CA2357986C CA 2357986 C CA2357986 C CA 2357986C CA 2357986 A CA2357986 A CA 2357986A CA 2357986 A CA2357986 A CA 2357986A CA 2357986 C CA2357986 C CA 2357986C
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- nucleic acids
- group
- nucleic acid
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne des acides nucléiques à extrémités bloquées tels que, par exemple, des oligonucléotides 2'-O-R, 2'-O-R-O-R, 3'-O-R et 3'-O-R-O-R, possédant une stabilité de pH faible, une résistance aux nucléases et éventuellement des propriétés antibactériennes. Ces acides nucléiques à extrémités bloquées, à faible toxicité, à haute spécificité et à stabilité acide représentent une nouvelle structure d'oligonucléotides améliorée destinée au traitement par voie thérapeutique d'affections. Les polymères résistants aux exonucléases à stabilité acide 3' et 5' de la présente invention possèdent des effets antibactériens lors de leur application in vivo, c.-à-d. lors de leur application topique sur une peau présentant des sites effectifs d'infection chez les chiens et les humains.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22349898A | 1998-12-30 | 1998-12-30 | |
US09/223,498 | 1998-12-30 | ||
US35606999A | 1999-07-19 | 1999-07-19 | |
US09/356,069 | 1999-07-19 | ||
PCT/US1999/030266 WO2000040592A1 (fr) | 1998-12-30 | 1999-12-16 | Acides nucleiques a extremites bloquees, squelette modifie et stabilite acide et leurs utilisations therapeutiques |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2357986A1 CA2357986A1 (fr) | 2000-07-13 |
CA2357986C true CA2357986C (fr) | 2014-02-11 |
Family
ID=26917847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2357986A Expired - Lifetime CA2357986C (fr) | 1998-12-30 | 1999-12-16 | Acides nucleiques a extremites bloquees, squelette modifie et stabilite acide et leurs utilisations therapeutiques |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1140966A1 (fr) |
JP (1) | JP4688294B2 (fr) |
AU (1) | AU2197600A (fr) |
CA (1) | CA2357986C (fr) |
WO (1) | WO2000040592A1 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU781577B2 (en) * | 1998-12-30 | 2005-06-02 | Lakewood-Amedex, Inc. | Therapeutic phosphodiesterase inhibitors |
CA2453362A1 (fr) | 2001-07-10 | 2003-01-23 | Oligos Etc. Inc. | Compositions pharmacologiques contenant des oligonucleotides et leur utilisation |
DE10361502A1 (de) * | 2003-12-23 | 2005-07-28 | Phenion Gmbh & Co. Kg | Kosmetische oder pharmazeutische Zubereitungen enthaltend Superstruktur-bildende Nukleinsäure-Sequenzen |
JPWO2012070618A1 (ja) | 2010-11-24 | 2014-05-19 | 株式会社カネカ | 増幅核酸検出方法及び検出デバイス |
CN104254620B (zh) * | 2012-04-27 | 2022-11-08 | 株式会社钟化 | 核酸的扩增方法及扩增核酸的检测方法 |
US20160068901A1 (en) * | 2013-05-01 | 2016-03-10 | Advanced Liquid Logic, Inc. | Analysis of DNA |
US10392652B2 (en) | 2013-11-22 | 2019-08-27 | Kaneka Corporation | Micro RNA detection method using two primers to produce an amplified double stranded DNA fragment having a single stranded region at one end |
US20170016894A1 (en) * | 2015-07-15 | 2017-01-19 | Orizhan Bioscience Limited | Detection Comprising Signal Amplifier |
JP7132911B2 (ja) | 2016-09-16 | 2022-09-07 | バイオ-パス ホールディングス, インコーポレイテッド | リポソームアンチセンスオリゴヌクレオチドとの併用療法 |
JP7284709B2 (ja) * | 2017-04-19 | 2023-05-31 | バイオ-パス ホールディングス, インコーポレイテッド | Bcl2阻害のためのp-エトキシ核酸 |
US11104941B2 (en) | 2018-09-28 | 2021-08-31 | Bioo Scientific Corporation | 5′ adapter comprising an internal 5′-5′ linkage |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4037363A1 (de) * | 1990-04-09 | 1991-10-10 | Europ Lab Molekularbiolog | 2-0-alkylnukleotide sowie polymere, die solche nukleotide enthalten |
US5658731A (en) * | 1990-04-09 | 1997-08-19 | Europaisches Laboratorium Fur Molekularbiologie | 2'-O-alkylnucleotides as well as polymers which contain such nucleotides |
JPH07501314A (ja) * | 1991-05-10 | 1995-02-09 | ハイブライドン インコーポレイテッド | 3′−末端封鎖されたオリゴヌクレオチド |
US5696248A (en) * | 1994-06-15 | 1997-12-09 | Hoechst Aktiengesellschaft | 3'-modified oligonucleotide derivatives |
IT1271684B (it) * | 1994-07-22 | 1997-06-04 | Consiglio Nazionale Ricerche | Oligonucleotidi antisenso complementari all'rna messaggero del recettore umano della urochinasi |
WO1996039414A1 (fr) * | 1995-06-01 | 1996-12-12 | Hybridon, Inc. | Groupes nouveaux de protection des bases pendant la synthese d'oligonucleotides |
US5849902A (en) * | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
-
1999
- 1999-12-16 AU AU21976/00A patent/AU2197600A/en not_active Abandoned
- 1999-12-16 CA CA2357986A patent/CA2357986C/fr not_active Expired - Lifetime
- 1999-12-16 EP EP99966442A patent/EP1140966A1/fr not_active Withdrawn
- 1999-12-16 JP JP2000592300A patent/JP4688294B2/ja not_active Expired - Fee Related
- 1999-12-16 WO PCT/US1999/030266 patent/WO2000040592A1/fr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP4688294B2 (ja) | 2011-05-25 |
CA2357986A1 (fr) | 2000-07-13 |
EP1140966A1 (fr) | 2001-10-10 |
WO2000040592A8 (fr) | 2000-11-09 |
JP2002534434A (ja) | 2002-10-15 |
WO2000040592A1 (fr) | 2000-07-13 |
AU2197600A (en) | 2000-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1140965B1 (fr) | Oligonucleotides protonés antibacteriens | |
DE69008521T2 (de) | Kovalente konjugate von lipiden und oligonukleotiden. | |
DE69513998T2 (de) | Verwendung von 2'-substituierten oligonukleotiden zur reduzierung der genexpression | |
EP1313768B1 (fr) | Oligonucleotides antisens contre vr1 | |
DE69931029T2 (de) | Optimierte antisense oligonukleotide komplementär zu dna-methyltransferase sequenzen | |
DE69629702T2 (de) | Liposomale oligonukleotidzusammensetzungen | |
DE69233117T2 (de) | In sich geschlossende "sens-" und "antisense"-oligonukleotide und deren verwendungen | |
US6001989A (en) | Nucleotide based endonucleases | |
CA2357986C (fr) | Acides nucleiques a extremites bloquees, squelette modifie et stabilite acide et leurs utilisations therapeutiques | |
EP2079313A2 (fr) | Composés antimicrobiens et antiviraux et leurs procédés d'utilisation | |
JP4787409B2 (ja) | 治療用ホスホジエステラーゼ阻害剤 | |
EP1204430B1 (fr) | Conjugats et procedes permettant de les preparer, et leur utilisation pour transporter des molecules par l'intermediaire de membranes biologiques | |
DE69613984T2 (de) | Für die protein-kinase a-spezifische modifizierte oligonukleotide und verfahren zur deren verwendung | |
DE19750702A1 (de) | Antisense Oligonucleotide gegen Tenascin zur Behandlung von Vitiligo | |
DE69302369T2 (de) | Erhöhung der katalytischen Aktivität von Ribozymen mit einem benachbartem Oligonukleotid als Heffer | |
AU2004226974B2 (en) | Protonated/acidified nucleic acids and methods of use | |
DE60208400T2 (de) | Therapeutisch verwendbare triethylenglykol-cholesteryl-oligonukleotide | |
DE10006572A1 (de) | Oligonucleotid-Konjugate | |
US6008343A (en) | Nucleotide based endonucleases | |
DE69835525T2 (de) | Verminderungsregulation der genexpression durch kolorektale verabreichung von synthetischen oligonukleotiden | |
AU650032B2 (en) | Endonucleases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20191216 |